Atnaujinkite slapukų nuostatas

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills.

Feldman explains the secretive world of drug pricing deals that push patients into more expensive drugs. This book is intended for an audience of policymakers, scholars, jurists, higher education students, journalists, and general interest readers and aims to provide an accessible, easy-to-read tour of issues faced by the pharmaceutical industry.

Daugiau informacijos

Examines the pharmaceutical industry to expose how higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines.
Preface;
1. Introduction;
2. The landscape where do the dollars flow;
3. PBMs and insurers;
4. Pharmacies, doctors, and patient groups;
5. May your
drug price be ever green;
6. Solutions.
Robin Feldman is the Arthur J. Goldberg Distinguished Professor of Law at the University of California Hastings. She is an award-winning scholar whose work has been called 'absolutely remarkable' and a 'must read'. Feldman has published four books and more than fifty articles, and she has been cited by the White House and members of Congress. In 2017, she participated in the GAO's report to Congress on Artificial Intelligence and in an Army Cyber Institute threatcasting exercise on weaponization of data.